An intensive analysis of the competitive landscape reveals that the Graves Orbitopathy Market has transformed into a high-stakes arena characterized by aggressive mergers, strategic alliances, and rigorous pipeline developments. Multinational biopharmaceutical companies are increasingly acquiring smaller, niche biotechnology startups that possess proprietary molecular platforms targeting the...